The shape-shifting telehealth company has spent the past year trying to cash in on GLP-1s, the hottest drug to hit weight loss in decades. It could all slip away. By Madison Muller and Devin Leonard
Listen to the Story
453 clip(s)
The CEO Playbook to Navigating Trump
The Dawn of Music’s AI Era
The Startup Making Human Embryos With AI-Assisted Robots